Physician profile
William Brawner
NPI 1053302125
$2,014.53
in general payments reported to CMS, 2019-2025
12 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $93.07 · 2022: $115 · 2023: $601 · 2024: $560 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $932.66 | 2022-2025 | Lensx, Argos, Clareon |
| Inspire Medical Systems, INC. | $211.65 | 2024-2025 | Inspire |
| Bausch & Lomb Americas INC. | $170.80 | 2023-2025 | Vyzulta, Miebo |
| Glaukos Corporation | $149.46 | 2024-2025 | Idose, Photrexa Viscous and Photrexa |
| Mallinckrodt Hospital Products INC. | $135.53 | 2023-2024 | Acthar |
| Abbvie INC. | $123.79 | 2023 | Durysta |
| Aerie Pharmaceuticals, INC. | $93.07 | 2020 | |
| Amgen INC. | $58.81 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $56.10 | 2024 | Syfovre |
| Oyster Point Pharma, INC. | $44.36 | 2025 | Ryzumvi, Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $22.46 | 2023 | Acuvue |
| Rxsight INC | $15.84 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Brawner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.